



**BioAlliance Pharma ranked as France's fastest growing company
in the 2011 « Deloitte Technology Fast 50 »**

Paris, November 18, 2011 – BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announced that it has won first prize in “Deloitte’s Technology Fast 50” 2011 ranking of fastest-growth technologies companies, as well first prizes “Biotech and Health sector” and “Nyse Euronext” in national Fast 50 ranking. BioAlliance Pharma also received first prize in regional “Ile-de- France Fast 50” ranking.

This ranking is drawn up according to turnover growth over the fiscal years 2006 to 2010. During this period, BioAlliance Pharma’s earnings substantially grew (4 800%) to reach €22.5 million in 2010. This strong increase is due to the steps successfully achieved on Loramyc® by the Company over the last years: development, registration, price negotiation and partnership on an international level.

“BioAlliance Pharma’s team is proud of these awards, symbolizing our know-how and expertise. We belong to the very few small- and medium-sized innovative companies in this area which have achieved all these steps. The domain of drug development is a path paved with difficulties where excellence, engagement and a dose of luck are the keys of success”, declares Judith Greciet, CEO of BioAlliance Pharma. “Through all these years, we have pursued a growth strategy based on a balanced product portfolio in terms of progress phases as well as market potential. It is the second time BioAlliance ranks first in the “Deloitte Technology Fast 50”; it represents a strong signal of our ability to create long-term value. This would have not been possible without our financial and industrial partners’ confidence and support all along the way”.

“Inclusion in the first technologies companies with strong growth is an impressive exploit. We heartily congratulate BioAlliance Pharma on being on Technology Fast 50 program at Deloitte and for its outstanding growth rate over 5 years”, declares Ariane Bucaille, partner in charge of the Technology Fast 50 at Deloitte.

About the Deloitte Technology Fast 50

The Deloitte Technology Fast 50 was established in San Jose, California, in 1995. The growing programme now spans the globe and supplements the broader Deloitte Technology Fast 500 initiative as the local winners are automatically entered into the Fast 500 programme.

The Technology Fast 500 EMEA pre-eminent technology awards programme is a ranking of Europe, the Middle East and Africa's fastest-growing technology companies based on percentage revenue growth over five years. To learn more about a Deloitte Technology Fast 50 programme in France, please visit our website: www.fast50france.com

About Deloitte

Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee, and its network of member firms, each of which is a legally separate and independent entity. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte Touche Tohmatsu Limited and its member firms. In France, Deloitte SA is the member firm of Deloitte Touche Tohmatsu Limited, and professional services are provided by its subsidiaries and affiliates.

Deloitte provides audit, tax, consulting, and financial advisory services to public and private clients spanning multiple industries. With a globally connected network of member firms in more than 150 countries, Deloitte brings world-class capabilities and deep local expertise to help clients succeed wherever they operate. Deloitte's approximately 182,000 professionals are committed to becoming the standard of excellence.

In France, Deloitte calls on diversified expertise to meet the challenges of its clients of all sizes from all industries - major multinationals, local micro-companies and medium-sized enterprises. With the expertise of its 6,500 professionals and partners, Deloitte is a leading player in audit and risk services, consulting, financial advisory services, tax & legal and accounting, based on a multidisciplinary offering and a set of action principles attuned to the requirements of our environment.

About BioAlliance Pharma

Dedicated to cancer and supportive care treatment with a focus on resistance targeting and orphan products — BioAlliance conceives and develops innovative products, for specialty markets especially in the hospital setting and for orphan or rare diseases.

Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products' commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.

BioAlliance Pharma has developed an advanced product portfolio:

Specialty products

Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 28 countries (EU, US, Korea)

Sitavir® (Acyclovir Lauriad™) (labialis herpes): Positive phase III final results; registration status

Fentanyl Lauriad™ (chronic cancer pain): Positive preliminary Phase I results

Orphan Oncology products

Livatag® (Doxorubicin Transdrug™) in primary liver cancer: Authorization for Phase III clinical trial

Clonidine Lauriad™ (mucositis): Phase II on going

AMEP® (invasive melanoma): Phase I on going

For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2010 Reference Document filed with the AMF on April 7, 2011, which is available on the AMF website (<http://www.amf-france.org>) or on BioAlliance Pharma SA's website (<http://www.bioalliancepharma.com>).

BioAlliance Pharma SA

Judith Greciet, CEO
Tel +33 1 45 58 76 00

judith.greciet@bioalliancepharma.com

Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00

nicolas.fellmann@bioalliancepharma.com

ALIZE RP

Caroline Carmagnol
Tel.: +33 6 64 18 99 59

caroline@alizerp.com

Deloitte France

Julia Debienne
Tel.: +33 (0) 1 55 61 41 69

jdebienne@deloitte.fr